Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, placebo controlled, double-blind, double-dummy, 3-period cross-over study in adult patients with autism spectrum disorders evaluating cognitive response, eye-gaze, and heart rate variability after single-dose oxytocin 8 or 24 IU intranasal administration using the OptiNose bi-directional nose-to-brain device.

Next Previous
Trial Profile

A randomized, placebo controlled, double-blind, double-dummy, 3-period cross-over study in adult patients with autism spectrum disorders evaluating cognitive response, eye-gaze, and heart rate variability after single-dose oxytocin 8 or 24 IU intranasal administration using the OptiNose bi-directional nose-to-brain device.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oxytocin (Primary)
  • Indications Autistic disorder; Pervasive child development disorders
  • Focus Therapeutic Use
  • Sponsors OptiNose; OptiNose AS

    • Most Recent Events

    • 06 Nov 2020 Status changed from recruiting to completed.
    • 06 Oct 2015 Status changed from planning to recruiting, as per Optinose media release.
    • 21 Jul 2015 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top